Kyowa Kirin Co., Ltd. TSE:4151

Kyowa Kirin : Announces Changes in Directors and Management Structure

Published

Source: MarketScreener

Kyowa Kirin Announces Changes in Directors and Management StructureTOKYO, February 9, 2026- Kyowa Kirin Co., Ltd. (TSE: 4151) will subject to approval at the Annual General Meeting of Shareholders scheduled to be held in March 2026, implement the following changes in directors and the management structure, as set forth below.

  1. Abolition of the Executive Officer System and Introduction of the C-suite Executive System Kyowa Kirin resolved in October last year to transition to a company with an Audit and Supervisory Committee in order to establish a swift and decisive decision-making and business execution structure amid today’s rapidly changing environment※¹. In addition, with the aim of enhancing the speed and quality of management decision-making and execution globally, Kyowa Kirin Group has decided to further evolve its management execution structure and introduce a new C-suite

    Executive framework. Under the One Kyowa Kirin structure, this framework is intended to strengthen corporate governance and update the overall system to better align with the execution structure. C-suite Executives—covering the Chairman of the Board, CxOs, Region Presidents, and the Orchard CEO—will be positioned as Kyowa Kirin’s leadership team and will be responsible for making decisions with accountability to internal and external stakeholders, transcending functional and regional boundaries and considering the management of the company as a whole. With the introduction of this framework, the current Executive Officer system will be abolished as of the

    conclusion of the General Meeting of Shareholders in March 2026. Among the current Executive Officers, those who will continue to play a central role in management execution in positions other than C-suite Executive will be appointed as Officers in Charge. Through these initiatives, we will more powerfully drive “Story for Vision 2030,” our strategy for realizing our vision.

    ※1 : Resolved by the Board of Directors and disclosed on October 30, 2025.

  2. Executive Personnel Changes（New Appointments, Position and Responsibility Changes）

  1. Candidates for the new Directors of the Board（Audit and Supervisory Committee）

    Director of the Board

    Executive Officer

    Head of the Internal Audit Department

    Kenji Shibata

    Effective Date: Upon the resolution at the Annual General Meeting of Shareholders scheduled to be held in March 2026

    Audit and Supervisory

    Committee (Full-time)

    Director of the Board Audit and Supervisory

    Committee

    Audit & Supervisory Board Member

    Yoko Wachi

    Director of the Board Audit and Supervisory

    Committee

    Director of the Board

    Hiroshi Kanno

    Director of the Board Audit and Supervisory

    Committee

    Board Member, International Federation of Accountants (IFAC)

    Director of the board, Olympus Corporation

    Kohei Kan

  2. Executive Personnel Changes (Position and Responsibility Changes)

Representative Director, Chairman of the Board※2

Representative Director, Chairman and Chief Executive Officer (CEO)

(Administration of Internal Audit Department,

Administration of Sales & Marketing Division)

Masashi Miyamoto

Representative Director、 President and Chief Executive Officer (CEO) ※2

(Responsible for Internal

Audit）

Representative Director, President and Chief Operating Officer (COO)※3

Abdul Mullick

Director of the Board,

Executive Vice President and Chief Scientific Officer（CSciO） (Responsible for Research）

Director of the Board, Executive Vice President and Chief Medical Officer (CMO)

(Responsible for Medical Affairs Department, Pharmacovigilance Division)

(Administration of Intellectual Property

Department, Research Division, Development Division)

Takeyoshi Yamashita

Effective Date: Upon the resolution at the Annual General Meeting of Shareholders scheduled to be held in March 2026

※2 Resolved by the Board of Directors and disclosed on December 11, 2025.

※3 The COO position will be abolished.

３．C-suite Executive Appointments

Effective Date: Upon the resolution at the Annual General Meeting of Shareholders scheduled to be held in March 2026

Representative Director, Chairman of the Board

Representative Director, Chairman and Chief Executive Officer (CEO)

Specific Director

(Administration of Internal Audit Department, Administration of Sales & Marketing Division)

Masashi Miyamoto

Representative Director, President and Chief Executive Officer (CEO)

(Responsible for Internal

Audit）

Representative Director, President and Chief Operating Officer (COO)

Abdul Mullick

Director of the Board,

Executive Vice President and Chief Scientific Officer

(CSciO）

(Responsible for Research）

Director of the Board, Executive Vice President and Chief Medical Officer (CMO)

(Responsible for Medical Affairs Department, Pharmacovigilance Division)

(Administration of Intellectual Property Department, Research Division, Development

Division)

Takeyoshi Yamashita

Chief Business Officer (CBO) (Responsible for Business

Development、Corporate Planning、Intellectual

Property）

Managing Executive Officer Chief Supply Chain Officer (CSCO)

(Responsible for Manufacturing Division) (Administration of SCM Department)

Yasuo Fujii

Chief People Officer (CPO) (Responsible for Human

Resources and General Affairs,

Corporate Communications）

Managing Executive Officer, Chief People Officer (CPO)

(Responsible for Human Resources Division)

Shoko Itagaki

Chief Supply Chain Officer (CSCO)

(Responsible for

Manufacturing、SCM）

Managing Executive Officer Chief Supply Chain Officer (CSCO)

(Responsible for Manufacturing Division)

(Administration of SCM Department)

Toshiyuki Kurata

Chief Compliance Officer (CCO)

(Legal, Regulatory Affairs, Compliance & Risk Management, Quality）

Managing Executive Officer Chief Compliance Officer (CCO)

(Responsible for Legal Department, Regulatory Affairs Department, Global Quality Management Department, CSR Promotion Department)

(Administration of Quality Division)

Yoshiko Mori

Chief Digital Transformation Officer (CDXO)

(ICT Solution、ODX）

Executive Officer

Chief Digital Transformation Officer (CDXO) and Head of ODX Department

(Responsible for ICT Solution Department)

Mitsuru Kameyama

Chief Medical Officer (CMO) (Responsible for Medical Affairs, Pharmacovigilance,

and Development）

Executive Officer

Vice President, Head of Research Division

Yoshifumi Torii

Chief Strategy Officer (CSO) (Responsible for Global

Product Strategy）

CEO and Managing Partner Sapientia Advisory Partners

Colin Sims

Chief Financial Officer (CFO) (Responsible for Procurement、

Finance）

Takeda Pharmaceutical Company Limited Japan Pharma Business Unit

JPBU Finance JPBU CFO

Koji Igarashi

Japan and APAC (JAPAC) Region President

Managing Executive Officer

Chief International Business Officer (CIBO)

(Responsible for International Business Planning Department）

Tomohiro Sudo

North America (NA) Region President

President, KKNA Director on Board of Directors,

Kyowa Kirin USA Holdings, Inc. & Kyowa Kirin, Inc. (KKNA)

Steve Schaefer

Europe, the Middle East, and Africa (EMEA) Region

President

President, Kyowa Kirin International plc

Julie Dehaene-Puype

Orchard Therapeutics CEO

Orchard Therapeutics CEO

Bobby Gaspar

4．Executive Personnel leaving the position

  1. Audit & Supervisory Board Member leaving the position

    ※4

    Audit & Supervisory Board Member (Full-time)

    Hiroshi Komatsu

    ※4

    Outside Audit & Supervisory Board Member (Full-

    time)

    Hajime Kobayashi

    ※4

    Outside Audit & Supervisory Board Member

    Mayumi Tamura

    ※4

    Audit & Supervisory Board Member

    Toru Ishikura

    Effective Date: Upon the resolution at the Annual General Meeting of Shareholders scheduled to be held in March 2026

    ※4：Resolved by the Board of Directors on October 30, 2025 to transition to a Company with an Audit and Supervisory Committee, and already disclosed.

  2. Executive Officers leaving the position

Effective Date: Upon the resolution at the Annual General Meeting of Shareholders scheduled to be held in March 2026

Managing Executive Officer Chief Financial Officer (CFO)

(Responsible for Corporate Communications Department、 Procurement Department) (Administration of Finance and Accounting

Department）

Motohiko Kawaguchi

Managing Executive Officer

Vice President, Head of Sales & Marketing Division

Hiroshi Sonekawa

Executive Officer

Fumihiko Kanai